The acquisition of TNB-486 further diversifies
T-cell engagers are emerging as a promising therapeutic approach in haematological malignancies and solid tumours, noted
TNB-486 is a bispecific antibody targeting CD19 on tumour cells and CD3 on T-cells. It is currently undergoing Phase I clinical trials in relapsed and refractory B-cell non-Hodgkin lymphoma patients.
By binding to both CD19, an antigen expressed on B-cells, and to the CD3 receptor on T-cells, TNB-486 activates and recruits T-cells to CD19-expressing tumours where they can elicit an immune response.
"By redirecting the body's natural immune response to target B-cell malignancies, TNB-486 alone or in combination with CD20-targeted therapy could potentially deepen clinical responses and improve patient outcomes," explained
"We believe this innovative molecule, which was designed to optimise the therapeutic window of T-cell activation, will enable us to explore novel combinations that have the potential to become new standards of care in this setting," he added.
With the acquisition of TeneoTwo and TNB-486,
The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances.
In
The post
© Russell Publishing Limited, 2022. All Rights Reserved., source